Infectious disease diagnostic company Day Zero Diagnostics announced today that it completed a venture equity financing worth $21 million.
Sands Capital led the financing round, while significant participation came from new investors including BD, Panacea Venture and Hongkou Capital, along with existing investors including Triventures and Golden Seeds.
To date, Zero Day Diagnostics has raised more than $33 million in venture capital financing and more than $10 million in non-dilutive funding, according to a news release. In May 2020, the company received $6.2 million of that non-dilutive funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Boston-based Day Zero Diagnostics’ develops sequencing-based diagnostic technologies for identifying the species and antibiotic resistance profile of a bacterial pathogen within hours. The company’s approach aims to save lives while reducing the economic burden of…